Testing effectiveness (Phase 2)Study completedNCT03809013
What this trial is testing
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
Who this might be right for
Urothelial Carcinoma
RemeGen Co., Ltd. 64